In particular, of the seven patients with intermediate and high risk nodules, one (15%) patient was carrying the MSH2 mutation, two (28%) were carrying the MLH1 mutation, and the two patients who previously had thyroid cancer were carrying the MSH6 and MSH2 mutations, respectively. This evidence concerns the gene MLH1 and thyroid cancer.